Source link : https://www.newshealth.biz/health-news/can-tumor-mutational-burden-guide-treatment-in-metastatic-breast-cancer/
A study presented at the San Antonio Breast Cancer Symposium examined whether tumor mutational burden (TMB) was associated with outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer patients treated with either pembrolizumab (Keytruda) or chemotherapy. Findings showed that patients with high TMB had numerically more favorable survival when treated with the immune checkpoint inhibitor. In […]
Author : News Health
Publish date : 2024-12-27 17:39:01
Copyright for syndicated content belongs to the linked Source.
inHealth